What is the treatment for hyperammonemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Hyperammonemia

The treatment of hyperammonemia requires immediate intervention with nitrogen scavengers, temporary protein restriction, intravenous glucose supplementation, and consideration for kidney replacement therapy (KRT) based on ammonia levels and clinical status. 1

Initial Medical Management

  • Immediately conduct further investigations while simultaneously initiating treatment when elevated ammonia levels are detected 2
  • Discontinue all oral protein intake temporarily to prevent further ammonia production 1, 3
  • Provide adequate calories (≥100 kcal/kg daily) through intravenous glucose and lipids to prevent catabolism 2, 1
  • Maintain glucose infusion rate at 8-10 mg/kg/min 2, 1
  • Administer intravenous lipids (0.5 g/kg daily, up to 3 g/kg daily) for caloric support 2, 1

Pharmacological Treatment

  • Use nitrogen-scavenging agents at ammonia levels >150 μmol/L 1, 3:
    • Intravenous sodium benzoate (maximum dose 12 g daily):
      • For patients <20 kg: 250 mg/kg given over 90 min as bolus then as maintenance over 24 h 2
      • For patients >20 kg: 5.5 g/m² given over 90 min as bolus then as maintenance over 24 h 2
    • Intravenous sodium phenylacetate:
      • For patients <20 kg: 250 mg/kg given over 90 min as bolus then as maintenance over 24 h 2
      • For patients >20 kg: 5.5 g/m² given over 90 min as bolus then as maintenance over 24 h 2
  • For suspected urea cycle disorders, add L-arginine hydrochloride 2, 1:
    • For OTC and CPS deficiencies:
      • Patients <20 kg: 200 mg/kg 2
      • Patients >20 kg: 4 g/m² 2
    • For ASS and ASL deficiencies:
      • Patients <20 kg: 600 mg/kg 2
      • Patients >20 kg: 12 g/m² 2
  • For hepatic encephalopathy, administer lactulose, which reduces blood ammonia levels by 25-50% 4, 5

Kidney Replacement Therapy (KRT)

  • Clinical status should be the primary determinant for initiating KRT 2
  • Consider KRT for 2, 1:
    • Rapidly deteriorating neurological status, coma, or cerebral edema
    • Persistently high blood ammonia levels >400 μmol/L refractory to medical measures
    • Rapid rise in ammonia levels >300 μmol/L within a few hours that cannot be controlled via medical measures

KRT Modality Selection

  • Continuous Kidney Replacement Therapy (CKRT) is the preferred first-line treatment due to fewer cardiovascular complications and lower risk of rebound hyperammonemia 2, 1
  • Continuous venovenous hemodialysis (CVVHD) enables higher ammonia clearance than continuous venovenous hemofiltration (CVVH) 2
  • Hemodialysis (HD) is most effective for rapidly reducing blood ammonia levels but has more complications than CKRT 1, 3
  • Peritoneal dialysis (PD) should only be used when other KRT modalities are unavailable 2

Protein Reintroduction and Ongoing Management

  • Gradually reintroduce protein (by 0.25 g/kg daily, up to 1.5 g/kg daily) within 48 hours after ammonia levels decrease 2, 1
  • Avoid prolonged protein restriction beyond 48 hours as protein catabolism will drive further ammonia production 2, 1
  • Monitor ammonia levels every 3-4 hours until normalized 3

Common Pitfalls and Caveats

  • Delayed recognition and treatment can lead to irreversible neurological damage 1, 3
  • Ammonia samples must be properly collected from free-flowing venous or arterial blood and processed quickly to avoid false elevations 1, 3
  • Duration of hyperammonemic coma >3 days is associated with poor prognosis 1
  • Nitrogen scavengers will be dialyzed along with ammonia during KRT but can still be effective when used concurrently 1, 3
  • For hepatic encephalopathy specifically, ammonia levels do not consistently guide lactulose dosing in clinical practice 6

References

Guideline

Hyperammonemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Hyperammonemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.